• Explore /
  • Poster
  • / Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial.

Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial.

Abstract Poster

Authors

null

Jaekyung Cheon

Department of Medical Oncology, CHA Bundang Medical Center, Seongnam, South Korea;

Jaekyung Cheon , Baek-Yeol Ryoo , Beodeul Kang , Hongjae Chon , Changhoon Yoo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT5134532

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr TPS634)

DOI

10.1200/JCO.2023.41.4_suppl.TPS634

Abstract #

TPS634

Poster Bd #

P3

Abstract Disclosures

Similar Posters

First Author: Changhoon Yoo

First Author: Takeshi Terashima

First Author: Lorenza Rimassa

First Author: Han Chong Toh